immunocore-logo-2018
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024 07:00 ET | Immunocore Holdings plc
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...
immunocore-logo-2018
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024 10:00 ET | Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
April 04, 2024 16:00 ET | Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore”...
immunocore-logo-2018
Immunocore presented two posters at CROI 2024
March 05, 2024 16:30 ET | Immunocore Holdings Limited
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
March 01, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 March 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
immunocore-logo-2018
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
February 28, 2024 07:34 ET | Immunocore Holdings Limited
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023;...
immunocore-logo-2018
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
February 22, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3...
immunocore-logo-2018
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
February 21, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 21 February...
immunocore-logo-2018
Immunocore Prices Upsized Convertible Senior Notes Offering
January 30, 2024 23:30 ET | Immunocore Holdings Limited
Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 30, 2024) Immunocore Holdings plc (Nasdaq: IMCR) today...
immunocore-logo-2018
Immunocore Announces Proposed Convertible Senior Notes Offering
January 29, 2024 16:05 ET | Immunocore Holdings Limited
Immunocore Announces Proposed Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 29, 2024) Immunocore Holdings plc (Nasdaq: IMCR), today...